Hesperos Inc.

Hesperos Inc. is a biotechnology startup based in the United States, founded in 2015, and has recently received a $1.90M grant investment from the National Institutes of Health on 25 August 2021. The company specializes in accelerating drug discovery by providing safety and efficacy testing of chemicals and novel therapeutics for the pharmaceutical, cosmetic, and food industries using its patented, Human-on-a-Chip platform. Hesperos' innovative technology brings together biologists, surface chemists, and engineers to produce some of the world's most advanced organs-on-a-chip platforms, recreating key components of organs in an interconnected, functional system. Their breakthrough technology enables unprecedented visibility into specific disease states and how the human body will respond to treatment, reducing the need for animal testing in drug discovery while enabling research into previously untreatable rare diseases. The company's functional, interconnected, human in vitro platform provides preclinical insight into the efficacy and toxicity of novel therapeutics, a process that previously required costly animal testing and human trials to determine. Hesperos' Human-on-a-Chip holds the potential to revolutionize the drug discovery process, offering a more ethical, cost-effective, and efficient path to bringing new drugs and treatments to market.